Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. The company provides immunology and inflammation, rare diseases, neurology, oncology, and other medicines and vaccines. It also offers poliomyelitis, pertussis, and haemophilus influenzae type b (Hib) pediatric vaccines; respiratory syncytial virus protection and hexavalent combination vaccines protecting against diphtheria, tetanus, pertussis, polio, Hib, and hepatitis B; influenza, booster, meningitis, and travel and endemic vaccines, which includes hepatitis A, typhoid, yellow fever, and rabies vaccines. In addition, the company has a collaboration and license agreement with Exscientia to develop up to 15 novel small-molecule for oncology and immunology; ABL Bio, Inc. to develop ABL301, a treatment for alpha-synucleinopathies; Innate Pharma SA for a natural killer cell engager program targeting B7-H3; and Blackstone Life Sciences to develop pivotal studies and clinical development program. Further, it has a collaboration agreement with IGM Biosciences, Inc. to develop, manufacture, and commercialize IgM antibody; Kymera Therapeutics, Inc. to develop and commercialize protein degrader therapies targeting IRAK4 in patients with immune-inflammatory diseases; Nurix Therapeutics, Inc. to develop novel targeted protein degradation therapies; Denali Therapeutics Inc. to treat a range of systemic inflammatory diseases, such as ulcerative colitis; and Adagene Inc. for the discovery and development of antibody-based therapies. Additionally, it has a collaboration with Scribe Therapeutics Inc. to develop genome editing technologies; and co-promotion service agreement with Provention Bio, Inc. for the commercialization of teplizumab. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was incorporated in 1994 and is headquartered in Paris, France.

Sanofi

In a report released today, Benjamin Jackson CFA from Jefferies maintained a Buy rating on Sanofi, with a price target of €100.00. Jackson CFA cove...

Jefferies Sticks to Its Buy Rating for Sanofi (SNYNF)

Sanofi ( ($SNY) ) just unveiled an update. In November 2025, Sanofi announced significant advancements in its pharmaceutical offerings. On November...

Sanofi Advances with Dupixent and Teizeild Approvals in November 2025

Polestar Automotive Holding UK PLC Sponsored ADR Class C ( ($PSNYW) ) has released its Q3 earnings. Here is a breakdown of the information Polestar...

Polestar Reports Strong Revenue Growth Amid Challenges

Polestar Automotive Holding Uk Plc Adr ( ($PSNY) ) has released its Q3 earnings. Here is a breakdown of the information Polestar Automotive Holding...

Synergy Chc Corp (($SNYR)) has held its Q3 earnings call. Read on for the main highlights of the call. The recent earnings call for Synergy CHC Cor...

Synergy CHC Corp’s Earnings Call: Growth Amid Challenges

Earnings reports, economic data, deals, and more make up the top stock market stories on Wednesday.


Morning News Wrap-Up: Wednesday’s Biggest Stock Market Stories!

Shares of Tesla’s ($TSLA) Swedish electric vehicle rival Polestar ($PSNY) fell over 9% to $0.72 per share during early trading on Wednesday. This c...

Tesla Rival Polestar Stock (PSNY) Tumbles on Q3 Loss, Reverse Split Plan

Sany Heavy Equipment International Holdings Co ( ($HK:0631) ) just unveiled an update. Sany Heavy Equipment International Holdings Co. has announce...

Sany Heavy Equipment Announces EGM and Shareholder Eligibility Details

The latest update is out from Sanofi ( ($SNY) ). On November 3, 2025, Sanofi announced the issuance of $3 billion in notes, including floating and ...

Sanofi Issues $3 Billion in Notes to Bolster Financial Strategy

Polestar Automotive Holding UK PLC Sponsored ADR Class C ( ($PSNYW) ) has issued an announcement. On October 31, 2025, Polestar Automotive Holding ...

Polestar Faces Nasdaq Compliance Challenge

Sanofi ( ($SNY) ) has shared an announcement. On October 22, 2025, Sanofi announced that its investigational drug, efdoralprin alfa, met all primar...

Sanofi’s Efdoralprin Alfa Achieves Key Milestones in AATD Emphysema Study

Sany Heavy Equipment International Holdings Co ( ($SNYYF) ) has released its Q3 earnings. Here is a breakdown of the information Sany Heavy Equipme...

Sany Heavy Equipment Reports Strong Financial Growth

Naturgy Energy Group (($GASNY)) has held its Q3 earnings call. Read on for the main highlights of the call. Naturgy Energy Group’s recent earnings ...

Naturgy Energy Group’s Earnings Call: Achievements and Challenges

Sanofi (($SNYNF)) announced an update on their ongoing clinical study. Sanofi has initiated a new clinical study titled ‘A Multinational, Multicent...

Sanofi’s New Study on Balinatunfib: A Potential Game-Changer for IBD Treatment

An announcement from Sanofi ( ($SNY) ) is now available. On October 28, 2025, Sanofi announced the successful pricing of a $3 billion bond issue ac...

Sanofi Successfully Prices $3 Billion Bond Issue

In a report released on October 24, Nicolas Pauillac from Kepler Capital maintained a Hold rating on Sanofi, with a price target of €95.00. The com...

Kepler Capital  Reaffirms Their Hold Rating on Sanofi (SNYNF)

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on SOPHiA GENETICS (SOPH – Research Report) and Sanofi ...

Current Quarter	$0.85	Next Quarter	$1.08
Current Year	$4.46	Next Year	$4.89
QoQ Growth	+27.1%	YoY Growth	+9.6%
3Y EPS CAGR	+0.0%	Target Price	$61.96
Consensus	Buy	Upside	+24.8%

Current Quarter Rev	N/A	Next Quarter Rev	N/A
Revenue Growth	N/A	YoY Growth	N/A

	A	B	C	D
1	Symbol	Price	Change	Volume
2	SNY	$49.63	+1.51%	3.34M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	SNY	$49.63	+1.5%	3.34M
3
4
5
6

SNY

SNY

EPS Estimates Overview

EPS Historical Trend (5 Years)

Quarterly EPS Estimates

Revenue Analysis

Get Sanofi Data in Excel

Get Sanofi Data in Excel